PDR MEMBER LOGIN:

Not a Member? Register Now

Forgot your password?

  • PDR Search

    Required field
  •  

  • PDR Update

    Labeling Updates as of March 1, 2023 - Issue 2

  • Labeling Updates

    • K e y
    • BlackBox_opt Boxed Warning
    • Triangle_opt Other Warnings*
      *Warnings and Precautions; Adverse Reactions; Drug Interactions; and Contraindications
    • Circle_opt Updates to Indications/Dosage
    • Diamond_opt Other Updates†
      †Other labeling changes; added to PDR database
    Triangle_opt
    Diamond_opt
    Avycaz (avibactam/ceftazidime)
    Triangle_opt
    Diamond_opt
    Liletta SHI (levonorgestrel)
    Diamond_opt
    Lo Loestrin Fe (ethinyl estradiol/ferrous fumarate/norethindrone acetate)
    Diamond_opt
    Ozurdex (dexamethasone)
    Triangle_opt
    Circle_opt
    Diamond_opt
    Rinvoq (upadacitinib)
    Diamond_opt
    Skyrizi (risankizumab-rzaa)
    Triangle_opt
    Circle_opt
    Diamond_opt
    Synthroid (levothyroxine sodium)
    Triangle_opt
    Circle_opt
    Diamond_opt
    Vraylar (cariprazine)
  •  

    To have full prescribing information faxed or mailed to you, call 1-800-261-2313.

    The FDA encourages healthcare professionals to recognize and report misleading prescription drug advertising. To report: call 855-RX-BADAD (855-792-2323) or email BadAd@fda.gov. For more information, visit www.fda.gov.
    Report adverse events to MedWatch.